Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
News|Articles|July 9, 2015
Mobile Cleanroom Doubles Available Space
Walker Barrier Systems extended-width mobile cleanroom provides 1350 square feet of workable space.
An extended-width mobile cleanroom from Walker Barrier Systems (part of Wabash National Corporation) provides 1350 ft2 of workable space, which is double the space of its standard-width model. All the company's cleanrooms include doors with windows, door closers, interlocks, adjustable sweeps, airlocks, cascading pressure operation between rooms, and dry chemical fire-suppression systems.
The units, constructed with Wabash National’s DuraPlate composite panel technology, are built to support a broad array of processes and platforms that are required to develop vaccines or contain biological agents.
“The extended-width clean rooms are approximately 48 feet long and 36 feet wide, providing full-scale manufacturing capabilities,” said Dave Nick, Wabash National’s vice president and general manager, Walker Engineered Products. “In addition, both standard- and extended-width models are designed to be joined together to create larger suites to fit specific application requirements. Our mobile clean rooms bring together Walker Barriers Systems’ leading solutions in isolation and containment into a rapidly deployable and flexible manufacturing facility.”
Source:
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.